Edelman Joseph's Form 4 filing
Landos Biopharma, Inc. (LABP) · filed Jan 11, 2023
- Accession no.
- 0001062993-23-000853
- Filed
- Jan 11, 2023, 6:45 PM ET
- Trade date
- Jan 10, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 derivative transactions. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Edelman JosephCIK 0001164426 | 10% Owner |
| Perceptive Advisors LLCCIK 0001224962 | 10% Owner |
| Perceptive Life Sciences Master Fund LtdCIK 0001249675 | 10% Owner |
| Perceptive Xontogeny Venture Fund, LPCIK 0001757940 | 10% Owner |
| Perceptive Xontogeny Venture Fund II, LPCIK 0001851820 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 10, 2023 | Common Stock | PPurchaseAcquired | +27,272,727 | $0.54 | +$14,727,272.58 | 27,272,727 | Indirect | |
| Jan 10, 2023 | Common Stock | PPurchaseAcquired | +3,636,363 | $0.54 | +$1,963,636.02 | 3,636,363 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.